The 18 stocks in the G-2 Diagnostic Stock Index dropped an average of 7 percent in the five weeks ended March 7, with 15 stocks down in price and three up. The S&P 500 has lost 11 percent so far this year, and the Nasdaq is down 15 percent.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

April 2008 - Table of Contents

DTTR April 2008 (full PDF issue)

JAMA Study Sends Chill Through IVD Market

Immucor Bets on Blood Genotyping

Third Wave Sees Clinical Revenue Grow 25% in '07

NEJM Study Probes Pharmacogenomics of Warfarin Metabolism

PerkinElmer Acquires Pediatrix’s Newborn Screening Lab

New Bioimaging System Promises Improved HER2 Testing

Ikonisys Boosts Automated FISH Platform with New Reference Lab

Quidel RSV Test Gets CLIA Waiver

Abbott to Co-Develop Pharmacogenomic Test for Lung Cancer Drug

Quest Diagnostics Signs Onto Google Health EHR

ACLA Presses SACGHS for Clarification on Genetic Testing Oversight

Beckman Coulter Launches High-Volume Testing System

IVD Stocks Fall 7%; Inverness Plummets 33%

Lung Cancer-Focused Allegro Diagnostics Raises $4 Million